Phylogenetic reconstruction shows no evidence drug-resistant minority variants (DRMinVs) in patients with recent HIV-1 infection result from a transmission event. Therefore the majority of DRMinVs in people recently infected are most likely generated de novo.
INTRODUCTION
The British HIV Association (BHIVA) HIV treatment guidelines recommend that genotyping is undertaken to rule out the presence of transmitted drug resistance (TDR) and to guide the selection of first-line therapy regimen in individuals with diagnosed primary HIV infection [1] . Currently, this is performed using Sanger capillary sequencing technology by most diagnostic laboratories in the UK with a lower mutation frequency (MF) threshold of 20%. Ultra-deep sequencing technologies capable of detecting variants present at a frequency down to 1% of the virus population e.g. next generation sequencing (NGS), are slowly being introduced into clinical microbiology diagnostic laboratories. However, the evidence for the clinical significance of drug-resistant minority variants (DRMinVs) is contradictory and more data is required to inform their interpretation in clinical management of HIV-infected individuals using validated assays and large scale clinical studies [2] [3] [4] [5] [6] [7] [8] [9] [10] .
HIV exists as a population of multiple variants within an infected host [11, 12] . A majority of HIV-1 infections are thought to result from the transmission of a single virus clone, thus multiple variants arise as a consequence of the error-prone nature of the HIV-1 replication mechanism [13] [14] [15] [16] . The genetic diversity generated through this process is a harbinger of drug-resistant variants which can lead to the failure of antiretroviral therapy (ART). Early detection of minority variants could therefore be of benefit to HIV-infected individuals undergoing ART.
Several factors may contribute to an association between DRMinVs and treatment failure. Mutational load, defined as the absolute copy number of drug-resistant variants per unit volume in an infected individual, is one factor [17] . This is a product of the MF and the patient's viral load e.g. at 1% MF, the absolute copy number in an individual with a viral load of 10 3 copies/mL would be 10 copies/mL compared to 10,000 copies/mL in an individual with a viral load of 10 6 copies/mL. The genetic barrier to resistance is often linked to the association of NNRTI DRMinVs with virological failure [18] . This is the number of genetic changes required for a virus population to acquire robust resistance against a drug regimen. For most NNRTI regimens it takes only one or two genetic changes to cause high-level resistance [19, 20] . The genetic linkage of two or more drug-resistant mutations (DRMs) directed against different antiretroviral (ARV) drug classes used in combination ART (cART) on a single genome is more likely to result in treatment failure than being present on separate genomes [21] . Other factors, such as adherence, pharmacodynamics and pharmacokinetics resulting in suboptimal drug concentrations could also favour the outgrowth and subsequent dominance of DRMinVs.
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However, it is also thought that the origin of a drug-resistant variant could influence whether it becomes clinically relevant. DRMinVs arising under drug selection, either in treatment-experienced individuals or by transmission, are more likely to establish a persistent infection and impact treatment outcome than those generated de novo in the absence of drug selection and as a consequence of viral replication [10, [22] [23] [24] [25] . The transmission of DRMinVs however contradicts the current understanding that most HIV infections arise from a single virus clone, although it is possible that the drug-resistant variant could be transmitted as the sole virus or a majority population followed by reversion to wild-type with residual persistence of the drug-resistant variant as a minority population. Several studies have investigated the origin or transmissibility of HIV-1 DRMinVs with inconsistent findings [10, [26] [27] [28] [29] .
We performed ultra-deep sequencing of partial HIV-1 pol gene from recently infected individuals in the UK sampled between 2011 and 2014 to detect sequences harbouring DRMinVs. We used a phylogenetic approach to investigate the origin of DRMinVs and determine if they are a result of a transmission event.
We performed transmission cluster analysis together with sequences from the UK-HDRD which contains the pol sequences from the vast majority of genotypic resistance test results performed in the UK since 1997.
METHODS

Samples and data collection
Between July 2011 and December 2014, 24,569 people were newly diagnosed with HIV-1 in England, Wales and Northern Ireland, of which 11,086 (45.1%) were tested using a recent infection testing algorithm (RITA) [30] . 2,043 (18.4%) were identified to have been infected within 5 months of sampling, of which 835 samples (i.e. 40.9% of recent infections) were subjected to NGS. This includes 442 samples from men who have sex with men (MSM) sampled between July 2011 and December 2013 [30] . We also performed NGS on 186 samples from newly diagnosed individuals determined by RITA to be from long-standing infections. Linked clinical and demographic data were extracted from the HIV and AIDS Reporting System (HARS) held at PHE. 111,807 partial pol sequences from 76,293 individuals generated by Sanger sequencing as part of routine clinical care in the UK from 1997 to 2014 collated by the UK-HDRD were also used.
Ultra-deep sequencing
A 1.3kb region of the HIV pol gene (all of protease and the N-terminal 320 amino acids of reverse transcriptase) was amplified and sequenced using Illumina MiSeq and the raw short-read data was analysed using an in-house bioinformatics pipeline [30] . The drug resistance sequences generated in this study have been submitted to GenBank (accession numbers MH663717 -MH663796).
Phylogenetic analyses
The sequences from recently infected patients generated using NGS were compared against the UK-HDRD sequences. To minimise the number of sequences incorporated into any subsequent phylogenetic analysis, the NGS sequences and the UK-HDRD sequences were clustered on the basis of sequence similarity. Each NGS sequence was compared against a database of the UK-HDRD sequences using the Basic Local Alignment Tool (BLAST) [31] . For each NGS generated sequence, an in-house Python script was used to identify all BLAST hits in the database with sequence identity >95% and these UK-HDRD sequences were put into clusters with the NGS generated sequences. Clusters were merged when the same UK-HDRD sequence was identified as being greater than 95% similar to two or more NGS sequences. Duplicate sequences from the same patient were removed after matching using linked epidemiological data, resulting in a final dataset comprising 9,182 sequences.
Sequences in the final dataset were aligned using MAFFT v7 [32] with minimal manual editing.
Maximum likelihood phylogenetic reconstruction was performed using FastTree v2.1.9 [33] with GTR model of nucleotide substitution. Transmission clusters were identified from the phylogenetic trees using Cluster Picker v1.2.3 [34] at 4.5% or 1.5% maximum genetic distance threshold between all sequences in the cluster and a 90% minimum clade support threshold (Shimodaira-Hasegawa (SH) test).
RESULTS
Population characteristics
The characteristics of the population of recently infected study participants are described in Table 1 . The majority were white men who acquired HIV through sex with other men (MSM). All participants were ART-naïve and the majority were infected with HIV-1 subtype B with a median age of 32 years [26-40; IQR].
Prevalence of drug-resistant majority and minority variants in people recently infected
Ultra-deep sequencing of the HIV-1 pol domain from the 835 recently infected individuals was performed to detect the presence of drug-resistant majority variants (DRMajVs) and DRMinVs. We 6 define DRMajVs as those present at a frequency >20%, the equivalent of the limit of detection of Sanger-based sequencing and DRMinVs as those present at a frequency between 2-20% [30] . Ninetythree DRMinVs were present in 84 of the 835 sequences ( 
No evidence for the transmission of DRMinVs in people with recent HIV-1 infection
We performed transmission cluster analysis using the NGS-generated sequences from recently infected (Figure 2) . Of the DRMajV sequences, 43 (65.2%) were in a transmission cluster with sequences that harboured the same DRM compared to only 3 (3.6%) of DRMinV sequences (p<0.00001; Fisher's exact test). Of the three DRMinV sequences two contained the D67G mutation in RT at 2.2% and 2.4% MF that were both present in the same transmission cluster together with 7 wildtype sequences. The third DRMinV sequence contained the K101E mutation in RT at 4.8% MF that was present in a transmission cluster that included one Sanger sequence with the K101E and M184I RT mutations and 7 wild-type sequences. Analysis of the distribution of DR-containing clusters showed that the majority of DRMajV NGS sequences (37/43; 86%) were present in transmission clusters where the majority of the sequences had the same DRM (Figure 3A) . In contrast, all DRMinV sequences were present in clusters where the majority of the sequences did not contain any DRMs (Figure 3B) .
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To limit detection to the most likely direct transmission events involving the NGS sequences from the acute infections, we used a genetic distance of 1.5% for transmission cluster analysis. This resulted in 28 
Relationship between MF, mutational load and transmission of DRMs
Further analysis of NGS data showed that a majority (46/50; 92.0%) of transmitted DRMs had a MF >90% compared to 1/50 (2.0%) with MF between 20-90% and 3/50 (8.0%) with MF <20% (Figure 4A) . A positive correlation was observed between mutational load and MF (r=0.51, p<0.001; Spearman's correlation) for the combined DRMajV and DRMinV dataset (Figure 4B) . In contrast, no correlation was observed between mutational load and MF (r=0.14, p=0.321) for the DRMinV dataset alone (Figure 4C) .
Similar relationships were observed when the analysis was limited to sequences within transmission clusters (Supplementary figure 1) .
DISCUSSION
This study used a phylogenetic approach to determine the derivation of HIV-1 DRMinVs in people who are recently infected in the UK. The presence of DRMs in this population is presumed to be a result of the transmission of a drug-resistant variant. It is thought that a TDR variant is more likely to persist because it was initially selected under drug pressure; however, the transmission of DRMinVs contradicts the current understanding that most sexually transmitted HIV-1 infections result from the transmission of a single clone. The relatively dense sampling of the UK HIV-1 epidemic enabled these analyses to be undertaken with high sensitivity. Unsurprisingly, the recent DRMajV and DRMinV NGS sequences were present in transmission clusters at a high percentage of 72.7% and 75.0%, respectively which is higher than the overall proportion of sequences in the UK HIV database that have previously been shown to be present in a transmission cluster at 52% [35] .
We observed a marked difference in the most common types of DRMajVs and DRMinVs in people recently infected, these being L90M and M46IL for PIs, T215rev and D67GN for NRTIs, and K103N and G190E for NNRTIs, for DRMajVs and DRMinVs, respectively. Furthermore, there is discordance in the proportion of DRMinVs in people recently infected and DRMs detected in individuals experiencing treatment failure in the UK by drug class [30] . For example, PI mutations account for the majority of DRMinVs detected at 52% whereas PI mutations are detected in less than 5% of people experiencing treatment failure in the UK (http://hivrdb.org.uk/). Correspondingly, we found no significant evidence It should be emphasized that these analyses do not rule out the possibility of DRMinV-to-DRMinV transmission. However, this is highly unlikely as it contradicts the current understanding that most HIV infections arise from the transmission of a single clone which would favour the transmission of the majority variant in sexual transmissions [13] [14] [15] [16] . On the other hand, we did observe two DRMinVs containing the D67G RT mutation in the same transmission cluster suggesting that DRMinV-to-DRMinV transmission could occur. This observation could either be a chance occurrence as the two sequences were not in a likely direct transmission cluster or the phylogenetic signal for direct relatedness could not reliably be discerned from the majority consensus sequences used in the phylogenetic reconstruction.
It is likely that DRMs are predominantly transmitted as a majority variant in recently infected individuals.
The DRMs subsequently decay, albeit at different rates, and are thus more likely to be detected as minority variants in newly diagnosed, treatment-naïve individuals with long-standing infections [36, 37] .
There was a slight, but not statistically significant, increase in DRMinVs linked to the same DRM in a transmission cluster for those with long-standing infection (11.8%; 2/17) compared to those with recent infection (3.6%; 3/84) (p=0.196) (Supplementary figure 2) . Of note, DRMinVs linked to transmitted resistance in both recent and long-standing infections were in RT and none were against protease even though the latter constituted the majority of DRMinVs detected in both populations. This suggests that DRMinVs in treatment-naïve individuals may not be created equal and only a few mutation types could result from a transmission event. This could also explain the association of NNRTI DRMinVs with virological failure observed in some studies whereas none have been reported to be associated with PIs [3, 8] .
Alternatively, DRMinVs could be a result of technical errors introduced during sample processing or due to de novo virus replication errors [10, 28, 38] . We have previously shown that the effect from the 9 former mostly contributes to variants detected below 2% in our assay and therefore are less likely to be the major source of the DRMinVs in this study as the variant threshold was set at 2% [30] . The replication process in HIV-1 is highly error prone and results in approximately one nucleotide mutation per genome per round of replication [39, 40] . Coupled with a high viral replication rate that can generate more than a billion virions in a single day in untreated individuals, it is postulated that a mutation occurs at every position in the HIV-1 genome every day. Interestingly, the most common DRMinVs were derived by G-A transition mutations, the most common replication error committed by HIV-1 and other lentiviral RTs [40] , whereas the DRMajVs were a result of transversion mutations or more than one transition/transversion mutation. This suggests a different origin for DRMajVs and DRMinVs, and that the latter could primarily be a result of viral and/or RT-PCR replication errors rather drug selective pressure. Of note, 87.5% of DRMajVs had a MF >90% whereas 90% of DRMinVs had a MF <10%. In addition, there was no correlation between mutational load and MF for DRMinVs also suggesting that most DRMinVs are likely generated de novo as a result of replication errors. These data indicate that a natural selection process may be at play resulting in preservation of DRMs with reduced effect on viral fitness and a purge of DRMs that have negative effect on viral fitness. This is in agreement with known effects on viral fitness of the common types of DRMajV and DRMinV described in this study [36, 41, 42] and the hypothesis that the frequency of minority variants is likely higher in recent infections because the effective population size is smaller and thus limits the effect of negative selection which exponentially increases later during the infection [28] .
In conclusion, we find no evidence that DRMinVs detected in people recently infected are a result of a transmission event suggesting that their detection to inform first-line treatment is unlikely to be of clinical benefit and might unnecessary limit treatment options. Most importantly, future longitudinal studies should focus on determining the treatment outcomes in the people identified to harbour the 
